Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone as PPAR gamma agonist

A technology of dimethylchalcone and gamma agonist, applied in the direction of ketone active ingredients, metabolic diseases, drug combination, etc., can solve the problems of increasing congestive heart failure, edema, weight gain, etc.

Inactive Publication Date: 2008-09-10
GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI +1
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thiazolidinedione (TZD) drugs, such as rosiglitazone and pioglitazone, are currently representative drugs targeting PPARγ for the treatment of type 2 diabetes, but these drugs usually cause weight gain and edema in clinical application , increased risk of congestive heart failure and other adverse outcomes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone as PPAR gamma agonist
  • Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone as PPAR gamma agonist
  • Application of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethyl chalcone as PPAR gamma agonist

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1D

[0016] Example 1 Analysis of PPARγ ligand-binding activity of DMC

[0017] 293T cells in the logarithmic growth phase were added to each well at 1.5×10 4 Cells were inoculated in 96-well culture plates, cultured overnight, and used for transfection when the cells grew to 80%-90% full. Dilute Lipofectamine2000 (volume ratio: 0.5:100) and plasmid DNA with OPTI-MEM medium, mix the diluted liposomes and plasmid DNA in equal volumes, place at room temperature for 20 minutes, and then transiently co-transfect the cells. The amount of plasmid DNA used was: GAL4-PPARγ-LBD 25ng per well, pFR-Luc 50ng per well, pRL-TK-Renilla 5ng per well. Incubate for 4 hours after transfection before adding drugs, the concentration of the experimental group is from 1n mol L -1 to 10μmol·L -1 The same volume of DMSO was added to the normal control group, and the luciferase activity was detected 24 hours after the addition of the drug. The detection method was strictly in accordance with the instruct...

Embodiment 2D

[0019] Example 2 Effect of DMC on the differentiation of 3T3-L1 preadipocytes

[0020] The 3T3-L1 preadipocytes cultured in a 24-well plate were grown to complete confluence 2 days later, and then replaced with induction solution (containing 200nmol·L -1 Insulin, 1 μmol L -1 Dexamethasone was cultured in 10% FBS high glucose DMEM), and at the same time, each well was added with a final concentration of 1 μmol L -1 , 5μmol·L -1 and 10 μmol L -1 DMC, the wells added with DMSO were used as normal controls, and after 3 days of induction, they were replaced with 200nmol·L -1 Insulin in 10% FBS High Glucose DMEM. After 2 days, the incubation was finished, and oil red O staining was performed: absorb all the medium, wash the cells once with PBS, fix the cells with 10% formaldehyde for 24 hours, discard the fixative, wash once with 60% isopropanol, and wait for the cells to fully After drying, add Oil Red O solution, stain at room temperature for 30 min, discard the dye, and wash...

Embodiment 3

[0022] Example 3 Effect of DMC on glucose uptake in 3T3-L1 adipocytes

[0023] The 3T3-L1 adipocytes in the 24-well culture plate were treated with 5 μmol·L -1 DMC and 5 μmol L -1 Rosiglitazone treated for 48h, DMSO treated cells as a normal control group. Before the glucose uptake test, the cells were replaced with 0.1% FBS-containing DMEM medium for starvation culture for 2 h, the medium was aspirated, the cells were washed with PBS three times, and replaced with 2% BSA-containing KRH buffer (20 mM HEPES, pH 7.4 ;136mmol L -1 NaCl; 4.7mmol L -1 KCl; 1.25mmol L -1 MgSO 4 ; 1.25mmol L -1 CaCl 2 ) at 37°C for 30 min, and the final concentration was 200 nmol L -1 Insulin continued to incubate at 37°C for 30min, then add 20μl containing 1.6μCi to each well [ 3 H]-2-deoxyglucose and 2-deoxyglucose mixed solution, incubate at 37°C for 10 minutes, quickly absorb the incubation solution, wash the cells 3 times with ice-cold PBS, and blow and lyse the cells with scintillat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of 2',4'-dihydroxyl-6'-methoxyl-3',5'-dimethyl chalcone as an agonist of PPAR-gamma of a peroxisome growth factor; the application of the compound as the agonist of the PPAR-gamma provides a novel drug for preventing and treating type II diabetes, hyperlipemia and adiposity.

Description

technical field [0001] The present invention relates to the use of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone as an agonist of peroxisome growth factor-activated receptor-γ (PPARγ) application. Background technique [0002] Peroxisome proliferator-activated receptors (PPARs) are a class of nuclear transcription factors activated by ligands and belong to the nuclear receptor superfamily. PPARγ is a subtype of PPAR mainly present in adipose tissue. After PPARγ is activated by binding to the ligand, it can form a heterodimer with the retinoid X receptor (RXR), and act on the PPAR-responsive element (PPAR-responsive element, PPRE) upstream of the target gene, thereby Regulate the transcription of target genes, which are directly or indirectly involved in many pathological and physiological processes, such as energy balance, cell differentiation, glucose and lipid metabolism, improvement of insulin resistance, etc. Therefore, drugs targeting PPARγ are currently a hot sp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/12A61P43/00A61P3/10A61P3/04
Inventor 吴东海金晓辉魏孝义黄志伟
Owner GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com